Dry age-related macular degeneration (AMD) with geographic atrophy (GA)
ANNXAnnexon Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Vonaprument (ANX007) (IVT) in Dry age-related macular degeneration (AMD) with geographic atrophy (GA). The expected timing is based on the latest available company guidance and may change.
ARCHER, ARCHER II, & ARROW trials. 8/5/24- Dosed in Ph3 trial. 10/17/24- New Ph2 ARCHER data at AAO '24. 7/24/25- Enrollment completed in ARCHER II w/ topline data in H2 2026. 8/8/25- Selected by EMA to participate in PDC pilot. 11/10/25:- Reiterated Ph3 ARCHER II enrollment completed in July. 01/12/26:- GA Investor Day planned March 2026; ARCHER II topline Ph3 GA data expected in H2 2026. 03/30/26:- ARCHER II topline Ph3 GA data expected Q4 2026; March 2026 retina-focused Investor Day held. 05/07/26:- Reiterated ARCHER II Ph3 GA topline data expected Q4 2026. 07/14/26:- ASRS oral presentation July 18, 2026. ARCHER II Phase 3 topline data expected Q4 2026. 08/12/26:- Added Month 24 dual primary endpoint; launched OLE. Month 15 topline and DMC assessment expected Q4 2026. 08/12/26:- ARCHER II Month 15 primary endpoint is expected in Q4 2026. Final trial completion with the Month 24 endpoint is expected in Q3 2027.
Verification
Confirm timing and program details against the company announcement or filing.